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Vps4 is a host factor known to be involved in cellular vacuolar protein sorting. We report here that HBV replication and secretion can be
significantly inhibited by Vps4 dominant negative, ATPase-defective, mutants K173Q and E228Q. In contrast, wild-type Vps4 at low dose can
inhibit HBV replication more effectively in human hepatoblastoma cell line HepG2, than in human hepatoma cell line Huh7. To our knowledge,
this is the first demonstration of an anti-HBV potential of dominant negative mutants of a protein sorting host factor Vps4.
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Human hepatitis B virus (HBV) is a major human pathogen.
Despite the fact that HBV vaccine is available, therapeutic
treatment of HBV remains a challenge. This is in part due to the
emergence of drug-resistant HBV variants (Shih, 2003;
Locarnini, 2005). Currently available treatments for HBV
include interferon, nucleotide and nucleoside analogs targeting
at HBV polymerase. Identification of new target, other than the
polymerase, should facilitate the development of anti-HBV
therapy. Virion release is an important step in the life cycle of all
viruses. Inhibition of HBV virion release could be an effective
measure to HBV therapy. Many different animal viruses,
including retroviruses, can utilize the so-called late domain
motifs (PT/SAP, PPXY, or YXXL) in their nucleocapsid or
matrix proteins for efficient virion release (reviewed in Demirov
and Freed, 2004). For example, the PTAP motif can be
recognized by a cellular factor Tsg101, which then links the
viral capsid to the vacuolar protein sorting machinery for virus
budding (Garrus et al., 2001; Licata et al., 2003). The PPXY⁎ Corresponding author. Fax: +1 409 747 2429.
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doi:10.1016/j.virol.2006.07.018motif, on the other hand, interacts with another cellular factor
Nedd4 (Demirov and Freed, 2004). Vacuolar protein sorting
(Vps4) is a member of the AAA (ATPase associated with a
variety of cellular activities) family of ATPases. Their cellular
functions include membrane fusion, protein degradation and
chaperone-like activities (Babst et al., 1998). Like other viruses,
HBV must utilize certain components of the host cellular
machinery for the egress of virions.
Results and discussion
A search of the HBV core protein (HBcAg) sequence reveals
the presence of two candidate late domain-like motifs, PPAY at
amino acids 129–132 and PNAP at amino acids 135–138
(unpublished results). Although the PPAYmotif is not conserved
in rodent hepadnaviruses (PAPY instead), it is conserved in all
mammalian hepadnaviruses (data not shown). Cryoelectron-
microscopic studies of HBV capsid structure have indicated that
HBcAg around amino acid 130 is exposed on the surface of
HBV capsid particles (Conway et al., 2003). While the presence
of these two candidate late domain-like motifs in HBV capsids
suggests the potential involvement of host factors in HBV
envelopment and virion release, HBV core mutations P130 T
(from PPAY to PTAY) and P135A (from PNAP toANAP) do not
appear to have any significant effect on viral replication or virion
2 Rapid Communicationsecretion in tissue culture (Yuan and Shih, 2000; Ponsel and
Bruss, 2003). It should be noted that HBV is generally believed
to bud into ER/Golgi (Ganem and Schneider, 2001), while type
C retroviruses are known to bud through the plasma membrane.
To further investigate this issue of HBV late domain-like motifs,
we asked if the vacuolar membrane protein sorting factor Vps4,
which has been shown to be involved in HIV virion release
(Garrus et al., 2001), could also play a role in HBV virion
release.
As shown in Fig. 1, 10 μg of wild-type HBV genomic dimer
DNA (subtype ayw) was cotransfected with various concentra-
tions of wild-type Vps4 (0.5 to 2 micrograms) into Huh7 cells
(Nakabayashi et al., 1982) using the calcium phosphate method.
HBV DNA of intracellular core particles was isolated as
previously described (Yuan et al., 1999a, 1999b). Southern blot
analysis of HBV DNA at various concentrations of Vps4
detected no significant and reproducible change of both
extracellular and intracellular HBV DNA (Fig. 1), indicating
the lack of effect of wild-type Vps4 on viral replication and
virion secretion.
Next, we cotransfected Huh7 cells with HBV and a
dominant-negative (DN) Vps4 mutant, K173Q, which is
defective in ATP binding. As shown in the Southern blot
result in Fig. 2A, unlike the wild-type Vps4, K173Q inhibitedFig. 1. Wild-type Vps4, at low concentrations, has no apparent effect on HBV
viral replication or secretion in Huh7 cells. Briefly, Huh7 cells were
cotransfected with 10 μg of HBV DNA (subtype ayw) and varying amounts
of wild-type Vps4 DNA. (A) Duplicate Southern blot analysis of virion DNA
present in cell culture media from transfected Huh7 cells. Virions were purified
via sucrose cushion and cesium chloride gradient ultra-centrifugation. (B)
Intracellular HBV core-associated DNA from transfected cell lysates was
subjected to Southern blot analysis with a 3.1 kb vector-free HBV specific
probe. RC: relaxed circular; SS: single-stranded.
Fig. 2. A dominant-negative Vps4 mutant, K173Q, at low concentrations, can
inhibit HBV viral replication and virion secretion. Huh7 cells were cotransfected
with 10 μg of HBV DNA (subtype ayw) and varying amounts of K173Q DNA.
(A) Southern blot analysis of virion DNA present in cell culture media from
transfected Huh7 cells. Virions were purified via sucrose cushion and cesium
chloride gradient ultra-centrifugation. (B) Intracellular HBV core-associated
DNA from transfected cell lysates was subjected to Southern blot analysis with a
3.1 kb HBV-specific probe. RC: relaxed circular; SS: single-stranded.HBV secretion in a dose-dependent and highly reproducible
manner. Even by using only 0.1 μg DNA of K173Q, we were
able to observe a 5-fold decrease in the amounts of secreted
virions compared to cells that were not cotransfected with
K173Q. This result is consistent with the dose-dependent
decrease of intracellular HBV replicative intermediates with
increasing amounts of K173Q DNA (Fig. 2B). Therefore, the
reduction of virion secretion by K173Q is at least in part due to
the effect of K173Q on intracellular HBV DNA synthesis.
Comparing the data in Figs. 1 and 2, K173Q is clearly more
potent in its inhibitory effect than its wild-type counterpart at
the same dose (e.g., 0.5 μg).
In addition, we noted that HBV virion secretion appears to be
more sensitive to the inhibitory effect of K173Q than the
intracellular viral DNA replication. For example, as little as
0.1 μg of K173Q DNA resulted in significant reduction of HBV
virion secretion (Fig. 2A), yet no significant effect on
intracellular HBV replication at this same dose (Fig. 2B).
These data indicate that the dominant negative mutant K173Q is
able to inhibit viral secretion at very low concentrations, while
inhibiting viral replication at higher concentrations.
To further explore the relationship between HBV and the
cellular factor Vps4, we performed similar transient
Fig. 3. Both dominant negative Vps4 mutants, K173Q and E228Q, can inhibit
HBV replication. Huh7 cells were cotransfected with 10 μg of HBV DNA
(subtype ayw) and 10 μg of either K173Q or E228Q DNA. Intracellular HBV
core-associated DNA from transfected cell lysates was subjected to Southern
blot analysis with a 3.1 kb HBV specific probe. RC: relaxed circular; SS: single-
stranded.
3Rapid Communicationcotransfection assay using the same wild-type HBV genomic
dimer and another dominant negative mutant E228Q, which is
defective in ATP hydrolysis. As shown in Fig. 3, 10 μg DNA of
either K173Q or E228Q significantly inhibited HBV replica-
tion. In addition, 10 μg wild-type Vps4 DNA can also decrease
HBV DNA replication by at least 4-fold, compared to cells that
were not cotransfected with Vps4. Taken together, dominant-
negative mutants of Vps4 are far more potent than wild-type
Vps4 in inhibiting HBV replication.
So far, our studies of the inhibitory effect of Vps4 used a
specific HBV subtype (ayw) and a specific cell line Huh7. WeFig. 4. Unlike Huh7 cells, HBV replication of both subtypes adr and ayw in HepG2 ce
manner. HepG2 cells were cotransfected with 10 μg of HBV DNA and varying am
transfected cell lysates was subjected to Southern blot analysis with a 3.1 kb HBV spe
HBV subtype adr.wish to address how general this anti-HBV phenomenon of
Vps4 is. To this end, we cotransfected a different cell line
HepG2 (Knowles et al., 1980) with a fixed concentration of
HBV DNA (10 μg DNA of subtype adr or ayw), and increasing
concentrations of Vps4 DNA. Five days post-transfection, core-
particle-associated HBV DNA was isolated and subjected to
Southern blot analysis. As shown in Fig. 4, unlike Huh7 cells,
HepG2 cells cotransfected with low concentrations of wild-type
Vps4 displayed a dose-dependent reduction of HBV DNA
replicative intermediates of both subtypes adr and ayw. Since
subtype adr does not replicate as well in Huh7 as in HepG2
cells (Suk et al., 2002), we were unable to test if subtype adr
can also be inhibited by mutant or wild-type Vps4 in Huh7 cells
(Fig. 1). The differential sensitivity of HBV subtype ayw
replication to the inhibition by wild-type Vps4 between HepG2
(Fig. 4) and Huh7 cells (Fig. 1), again highlights another
important difference between these two hepatocyte cell lines
commonly used in many research laboratories.
To determine if the reduced HBV replication by mutant or
wild-type Vps4 is due to cytotoxicity in host cells, we
performed the cytotoxicity assay using HepG2 or Huh7 cells
transfected with wild-type Vps4 or mutants (K173Q or
E228Q). We did not detect any apparent cytotoxicity in either
HepG2 or Huh7 cells transfected with 10 μg wild-type Vps4 or
2 μg K173Q DNA (Table 1), as determined by the amounts of
lactate dehydrogenase released into the cell culture media
(Materials and methods).
At present, it remains unclear what could be the mechanism
behind the phenomenon of HBV inhibition by mutant K173Q,
E228Q or wild-type Vps4. To address this issue, we examined
the HBV core protein production in the presence or absence of
wild-type or mutant Vps4. As shown in Fig. 5A, when
excessive amount of wild-type Vps4 DNA was used, we canlls, can be inhibited by wild-type Vps4 at low concentrations in a dose-dependent
ounts of wild-type Vps4 DNA. Intracellular HBV core-associated DNA from
cific probe. RC: relaxed circular; SS: single-stranded. (A) HBV subtype ayw; (B)
Table 1
No significant cytotoxicity in Huh7 cells transfected with wild-type or mutant Vps4
Mock-transfection
control
Carrier DNA
control
Vps4
(10 μg)
K173Q
(10 μg)
E228Q
(10 μg)
K173Q
(2 μg)
K173Q
(0.1 μg)
Freeze-thaw 20% ethanol
1.51±0.43 1.49±0.12 1.63±0.07 1.72±0.02 1.65±0.09 1.59±0.08 1.49±0.02 2.72±0.36 2.53±0.17
Note. Cell culture media from non-transfected and transfected cells were used for cytotoxicity assay as described in Materials and methods. Carrier DNA: cells were
transfected with carrier DNA only; Freeze-thaw: non-transfected cells were lysed by 2 repeated cycles of freeze-thaw at −80 °C in the presence of medium, and 50 μl
aliquot was then used for cytotoxicity assay; 20% ethanol: non-transfected cells were treated with ethanol (final concentration 20%) for 8 h. Absorbance was measured
at 490 nm.
4 Rapid Communicationdetect the GFP-Vps4 fusion protein, but not the HBV core
protein by Western blot analysis. Similarly, we detected
increasing Vps4 protein production when the dose of E228Q
plasmid DNA was increased (Fig. 5B, upper panel). However,
consistent with the Southern blot results, the steady state level
of HBV core protein was rapidly decreased simultaneously
(Fig. 5B, lower panel). The inverse correlation between DN
mutant E228Q protein and HBV core protein levels does not
necessarily argue for an inhibitory effect on HBV replication by
mutant E228Q through the reduction of HBV core protein. It is
equally possible that the reduction of HBV core protein by
E228Q is the consequence, rather than the cause, of reduced
HBV DNA synthesis. It would be interesting to dissociate the
cause–effect relationship between the reductions of HBV DNA
synthesis and HBV core protein in the future. Perhaps, it is also
worth mentioning that the increasing amount of E228Q protein
(Fig. 5B, upper panel), also argues against the possibility that
the reduction of HBV DNA (Fig. 3) and core protein (Fig. 5B,
lower panel) by mutant E228Q could be due to nonspecific
cytotoxicity.
The Vps4 pathway sorts membrane-bound proteins for
degradation (Lemmon and Traub, 2000), or in the case of
viruses, assists virions for budding (Garrus et al., 2001). We
therefore anticipated that Vps4 could affect HBV virion
secretion. Consistent with this prediction, we observed
reduced virion secretion by cotransfection with K173Q at
low dose (Fig. 2A). However, to our surprise, we also
observed inhibition of intracellular HBV replication by
ATPase-defective mutant K173Q (Fig. 2B). Previously, it
has been shown that the deficiency of envelopment can result
in preferential accumulation of the more mature HBV genomeFig. 5. An inverse correlation between dominant negative mutants E228Q and the ste
cells were cotransfected with 2 μg of HBV DNA (subtype ayw) and (A) wild-type Vp
at 48 h post-transfection. Goat anti-GFP antibody was used to identify the GFP-Vps
identify HBV core protein (Chua et al., 2005). (A) Amount of wild-type Vps4 DNA
DNA in lane 3: 0 μg; lane 4: 0.5 μg; lane 5: 1 μg. GFP-Vps4 and GFP-E228Q fusion
HBV core protein (HBc) in the lower panel bands at 23 kDa position on 12% SDS-P
similar to panel B, upper panel, was obtained by using anti-GFP mouse monoclonawith the near full-length size of HBV relaxed circle (RC)
DNA, banding at the 4.0 kb position on the 1% agarose gel
(Melegari et al., 1997; Yuan et al., 1999a; Chua et al., 2005).
The fact that no preferential accumulation of the 4.0 Kb RC
DNA in Fig. 2B suggests that K173Q is not a specific
inhibitor of HBV envelopment and virion secretion. Indeed,
the reduction of HBV replicative intermediates by K173Q
includes the entire spectrum of various HBV DNA forms
(single-stranded SS DNA and partially double-stranded RC
DNA). The data in Fig. 2B suggest that K173Q can inhibit
the intracellular HBV replication at step(s) prior to capsid
envelopment.
At present, we entertain several explanations for the Vps4
effect on HBV replication. One explanation is that Vps4, as a
membrane protein sorting factor, could be important for HBV
capsids to traffic to a certain specialized membrane compart-
ment (a niche) for most efficient replication. Alternatively, Vps4
could serve as an integral component of such a specialized
membrane compartment which provides a favorable micro-
environment for HBV packaging, capsid assembly or viral
DNA synthesis. Another potential explanation is that the effect
of Vps4 on HBV replication could be more indirect. For
example, it has been shown previously that ATPase-defective
Vps4 can impair cholesterol trafficking (Bishop and Woodman,
2000). The replication defect of HBV could be a direct or
indirect consequence of a kinetic block in postendosomal
cholesterol sorting.
Previously, it has been shown that the ATPase activity of
Vps4 is cooperative and reliant on formation of oligomers
(Babst et al., 1998). Therefore, it is likely that DN mutant Vps4
can functionally inactivate the wild-type Vps4 counterpart viaady state level of HBV core protein was shown by Western blot analyses. Huh7
s4 DNA; or (B) increasing amounts of E228Q DNA. Cell lysates were harvested
4 protein (Materials and methods), while rabbit anti-HBc antibody was used to
in lane 1: 0 μg; lane 2: 5 μg; (B) Amount of dominant negative mutant E228Q
proteins, as shown in the upper panel, migrated near the 75 kDa position, while
AGE. Data in both upper and lower panels are taken from the same gel. A result
l antibody B2 (Santa Cruz Co.) (data not shown).
5Rapid Communicationheterodimerization. The reason that, at higher concentrations,
wild-type Vps4 can also be inhibitory to HBV replication, is
less clear. It is possible that proper stoichiometry of WT
Vps4, relative to other host factors, could be important for its
normal function in the internal membrane protein sorting
machinery.
It should be mentioned that several cellular restriction factors
against retrovirus have been reported recently (Goff, 2004). In
the case of HBV, it has also been found that overexpression of
the SR-domain protein kinase (SRPK) can suppress HBV
replication (Zheng et al., 2005). Whether Vps4 can be
considered as a host restriction factor against HBV remains to
be determined. The absence of host permissive factors (e.g.,
caused by endogenous depletion) should be distinguished from
the presence of dominant-acting host factors (e.g., interferons).
Furthermore, because of the absence of an in vitro HBV
infection system, the suppression effect of SRPK or mutant
Vps4 is defined by cotransfection, rather than by the infection
assay. Therefore, it may not be straightforward to compare host
factors defined by different viral systems using different
functional assays.
In summary, we demonstrated here that (1) a dominant-
negative mutant K173Q can decrease HBV replication,
secretion, and the steady state level of HBV core protein; (2)
wild-type Vps4, at higher concentrations, can also inhibit HBV
replication; and (3) HBV replication is more sensitive to wild-
type Vps4 inhibition in HepG2 than Huh7 cells. These findings
may be exploited for further development in anti-viral therapy
by using Vps4 as a potential drug target. The detailed
mechanism of Vps4-mediated inhibition of HBV replication is
currently under investigation.
Materials and methods
The methods of cell culture, calcium phosphate transfection,
preparation of core and virion particles, DNA extraction and
Southern blot analysis were conducted as described elsewhere
(Yuan et al., 1999a, 1999b).
Plasmids
Plasmids containing the genomic dimer of wild-type HBV
DNA (subtypes adr and ayw) have been described previously
(Yuan et al., 1999a, 1999b). Plasmids of green fluorescence
protein (GFP) fused with wild-type Vps4 and mutant E173Q
and E228Q were kindly provided by Wesley Sundquist (Garrus
et al., 2001).
Cytotoxicity assay
The CytoTox 96 non-radioactive cytotoxicity assay was
performed as described by the manufacturer (Promega,
Madison, WI). Briefly, cell culture media were collected
3 days post-transfection from transfected Huh7 or HepG2
cells. Fifty microlitres of cell culture media was mixed with
50 μl of lactate dehydrogenase (LDH) substrate in a 96-well
plate, and incubated for 30 min at room temperature. Fiftymicrolitres of stop solution was then added to each well
before the absorbance reading at 490 nm. Media of negative
controls were also collected from non-transfected cells or cells
transfected only with carrier DNA. Positive controls were
included by treating the non-transfected cells with ethanol
(final concentration 20%) or two repeated cycles of freeze-
and-thaw.
Western blot analyses
Standard procedures of Western blot were followed. Cell
lysates were harvested at 48 h post-transfection. Horseradish
peroxidase (HRP)-conjugated goat anti-GFP antibody was
purchased from GeneTex Co. and used at 1:4000 fold dilution.
This antibody was used to identify the GFP-Vps4, GFP-E228Q
and GFP-E173Q fusion proteins. Rabbit anti-HBc polyclonal
antibody was used to identify HBV core protein (Chua et al.,
2005). Secondary antibody of goat-anti-rabbit (BioRad Co.)
was used at 1:1000-fold dilutions in PBS containing 0.5% non-
fat milk. The ECL detection kit from Amersham Co. was used
in all experiments.
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